We are updating the design of this site. Learn more.
Show more
ClinicalTrials.gov
ClinicalTrials.gov Menu

Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)

The recruitment status of this study is unknown. The completion date has passed and the status has not been verified in more than two years.
Verified December 2014 by University Hospital, Ghent.
Recruitment status was:  Recruiting
Sponsor:
ClinicalTrials.gov Identifier:
NCT01116804
First Posted: May 5, 2010
Last Update Posted: December 5, 2014
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Read our disclaimer for details.
Collaborator:
University Ghent
Information provided by (Responsible Party):
University Hospital, Ghent
  Purpose

Present imaging modalities for primary liver cancer (hepatocellular carcinoma or HCC) have several shortcomings. One important shortcoming is the time delay between successful treatment and radiological confirmation of this response. Often it takes several months for anatomical changes to occur and to be appreciated on morphological imaging such as CT or MRI (shrinkage of tumor, absence of contrast enhancement). Functional imaging by means of Fluor-18 deoxyglucose or Fluor-18 Choline (positron emitters, PET-scan) might be an early indicator of response. This "early" information might help to tailor treatment. For instance, if no response is induced, an early switch in therapy can be planned.

The present study investigates whether the routine PET-tracer (Fluor-18 deoxyglucose) and the experimental PET-tracer, Fluor-18 Choline help to predict response if a patient with inoperable primary liver cancer is treated (radionuclide therapy, biologicals).


Condition Intervention Phase
Primary Liver Cancer Procedure: MRI of the liver before start of treatment Procedure: MRI after treatment Procedure: PET-scan before treatment start Procedure: PET scan after treatment Phase 1

Study Type: Interventional
Study Design: Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Diagnostic
Official Title: Role PET Imaging in Response Assessment for Hepatocellular Carcinoma (HCC)

Resource links provided by NLM:


Further study details as provided by University Hospital, Ghent:

Primary Outcome Measures:
  • To evaluate the efficacy of PET-imaging versus classic response assessment (MRI, CT-scam) in patients with inoperable liver cancer [ Time Frame: 6 months after start of treatment ]

Estimated Enrollment: 75
Study Start Date: May 2010
Estimated Study Completion Date: October 2015
Estimated Primary Completion Date: July 2015 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
inoperable liver cancer patients Procedure: MRI of the liver before start of treatment
MRI of the liver as classic work out of patients (CT-scan if MRI is contra-indicated)
Procedure: MRI after treatment
MRI of the liver after 3 - 6 months of treatment (CT-scan if MRI is contra-indicated)
Procedure: PET-scan before treatment start
PET-scan with 2 tracers is performed before treatment start
Procedure: PET scan after treatment
PET-scan with 2 tracers is repeated 4 weeks following start of treatment

  Eligibility

Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria :

  • Male and female are eligible

    ->18years of age.No upper age limit.

  • not pregnant or breastfeeding
  • capable of understanding the study goals and protocol and to sign the informed consent.
  • Patients are diagnosed with primary liver cancer and referred for treatment with biologicals such as Sorafenib or treatment with radionuclides.
  Contacts and Locations
Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT01116804


Contacts
Contact: Bieke Lambert, MD bieke.lambert@ugent.be

Locations
Belgium
University Hospital Ghent Recruiting
Ghent, Belgium
Principal Investigator: Bieke Lambert, MD         
Sub-Investigator: H. Van Vlierberghe, MD, PhD         
Sub-Investigator: R. Troisi, MD, PhD         
Sub-Investigator: L. Defreyne, MD, PhD         
Sub-Investigator: P. Smeets, MD         
Sponsors and Collaborators
University Hospital, Ghent
University Ghent
Investigators
Principal Investigator: Bieke Lambert, MD University Hospital, Ghent
  More Information

Additional Information:
Responsible Party: University Hospital, Ghent
ClinicalTrials.gov Identifier: NCT01116804     History of Changes
Other Study ID Numbers: 2010/115
First Submitted: May 3, 2010
First Posted: May 5, 2010
Last Update Posted: December 5, 2014
Last Verified: December 2014

Keywords provided by University Hospital, Ghent:
Primary liver cancer

Additional relevant MeSH terms:
Carcinoma, Hepatocellular
Liver Neoplasms
Adenocarcinoma
Carcinoma
Neoplasms, Glandular and Epithelial
Neoplasms by Histologic Type
Neoplasms
Digestive System Neoplasms
Neoplasms by Site
Digestive System Diseases
Liver Diseases
Liver Extracts
Hematinics